Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioNotebook: Bayer invests in Versant's VC fund; corporate venture data; Triphase/Celgene deals

This article was originally published in Scrip

Executive Summary

Bayer HealthCare will invest up to $25m in the fifth venture capital fund raised by Versant Ventures, which may exceed $300m, to finance early-stage therapeutic innovation and extend the company's relationship with the VC firm.

You may also be interested in...



With Celgene Acquisition Closed, Bristol Faces Major Milestones

Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue. 

Billions On The Line With Celgene’s Partnered Pipeline

Celgene’s fourth quarter and 2016 sales aligned with previously disclosed double-digit gains as the company outlined later-stage pipeline programs expected to add billions in sales during the next five years.

Bayer's CoLaborator: A Startup Hub In San Francisco's Biotech Cluster

Bayer is incubating startups and nurturing companies that could be the big pharma's next partners at its CoLaborator in San Francisco's Mission Bay, the heart of the region's biotech hub.

Topics

Related Companies

UsernamePublicRestriction

Register

SC026836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel